All Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cance, Nerouology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers' and Babies Health. Clinical trials are an essential component of helathcare. They provide the evidence to evaluate the safety and efficacy of new treantments and diagnositics, and provide alternative treatment options for patients with unmet needs.
PUERTA: A novel treatment for patients in acute respiratory distress
ALT-100-002: Pioneering the Utility of eNAMPT-Reducing Therapies in Acute Respiratory Distress Syndrome [ARDS]/ ventilator-induced lung injury.
QUASAR Jr
The purpose of this study is to evaluate the effectiveness of guselkumab in pediatric participants with moderately to severely active ulcerative colitis through open label induction and through maintenance therapy among participants who were induction responders.
RAISE A clinical trial of a ganaxalone in status epilepticus
RC-48
The trial is testing a potential new treatment called disitamab vedotin for Muscle-invasive Bladder Cancer.
Healing and Disease-Modifying Effect of Guselkumab in Crohn’s Disease Patients
SNDX-6352-0506 - Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Axatilimab is a “monoclonal antibody”, which is an antibody manufactured in a laboratory. It is designed to specifically block a protein believed to be involved in lung fibrosis. By blocking this protein, Axatilimab may slow or stop the progression of IPF.
SPECIFI-CD - A potential new treatment for Crohn's Disease (CD)
SWIFT - Do you have Moderate to Severely Active UC?
The IPPaM Study - Does Light-Therapy Reduce Osteoarthritis Knee Pain and Aid Willingness to Exercise?
An Investigation of the effects of Photobiomodulation (PBM) therapy on Pain and functional Mobility in people with knee osteoarthritis not awaiting knee replacement surgery (a pilot study with wait-list control)
TROPION-Lung10
TROPION-Lung10: First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression